VTVT•benzinga•
vTv Therapeutics Says FDA Has Lifted Clinical Hold On Cadisegliatin Program For Diabetes, CATT1 Phase 3 Trial Expected To Resume Following Submission Of Protocol Amendment Shortening Overall Duration Of Trial From 12 To 6 Months
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga